We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

In a report released on February 28, Eric Joseph from J.P. Morgan maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with ...

Shares of AKRO stock opened at $45.54 on Monday. The stock’s 50-day moving average is $39.27 and its 200 day moving average is $32.78. Akero Therapeutics has a 1-year low of $17.86 and a 1-year ...

In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best booming stocks to invest in now. The U.S. stock market closed on a downbeat ...

Y Intercept Hong Kong Ltd lessened its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 47.1% in the fourth ...

Catriona Yale, the Chief Development Officer of $AKRO, sold 14,467 shares of the company on 01-27-2025 for an estimated $809,428. We received data on the trade from a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against the other biotech stocks. No matter the market environment, you’ll always find ...

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product ...